155 related articles for article (PubMed ID: 31913907)
1. Predictors of Distant Recurrence Following Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
Wong JK; Shaikh T; DeMora L; Zhang E; Borghaei H; Hayes SB; Kumar S; Meyer JE; Hallman MA
Am J Clin Oncol; 2020 Apr; 43(4):243-248. PubMed ID: 31913907
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Distant Failure After Stereotactic Body Radiation Therapy for Stages I to IIA Non-Small-Cell Lung Cancer.
Miller CJ; Martin B; Stang K; Hutten R; Alite F; Small C; Emami B; Harkenrider MM
Clin Lung Cancer; 2019 Jan; 20(1):37-42. PubMed ID: 30279109
[TBL] [Abstract][Full Text] [Related]
3. Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.
Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
Clin Lung Cancer; 2017 Mar; 18(2):e137-e142. PubMed ID: 27908620
[TBL] [Abstract][Full Text] [Related]
4. Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)?
Diamant A; Chatterjee A; Faria S; Naqa IE; Bahig H; Filion E; Robinson C; Al-Halabi H; Seuntjens J
Radiother Oncol; 2018 Sep; 128(3):513-519. PubMed ID: 29801721
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
Cerra-Franco A; Liu S; Azar M; Shiue K; Freije S; Hinton J; Deig CR; Edwards D; Estabrook NC; Ellsworth SG; Huang K; Diab K; Langer MP; Zellars R; Kong FM; Wan J; Lautenschlaeger T
Clin Lung Cancer; 2019 May; 20(3):186-193.e3. PubMed ID: 30711394
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
7. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
[TBL] [Abstract][Full Text] [Related]
8. Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
Baine MJ; Verma V; Schonewolf CA; Lin C; Simone CB
Lung Cancer; 2018 Apr; 118():20-26. PubMed ID: 29571997
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy for stage I non-small cell lung cancer: The importance of treatment planning algorithm and evaluation of a tumor control probability model.
Ohri N; Tomé W; Kalnicki S; Garg M
Pract Radiat Oncol; 2018; 8(2):e33-e39. PubMed ID: 29233523
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
[TBL] [Abstract][Full Text] [Related]
11. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
[TBL] [Abstract][Full Text] [Related]
12. Lobectomy Versus Stereotactic Body Radiotherapy in Healthy Octogenarians With Stage I Lung Cancer.
Razi SS; Kodia K; Alnajar A; Block MI; Tarrazzi F; Nguyen D; Villamizar N
Ann Thorac Surg; 2021 May; 111(5):1659-1665. PubMed ID: 32891656
[TBL] [Abstract][Full Text] [Related]
13. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.
Grills IS; Hope AJ; Guckenberger M; Kestin LL; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Belderbos J
J Thorac Oncol; 2012 Sep; 7(9):1382-93. PubMed ID: 22843086
[TBL] [Abstract][Full Text] [Related]
14. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
[TBL] [Abstract][Full Text] [Related]
15. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
Yan SX; Qureshi MM; Dyer M; Truong MT; Mak KS
Lung Cancer; 2019 May; 131():147-153. PubMed ID: 31027693
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
19. Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance.
Spratt DE; Wu AJ; Adeseye V; Din SU; Shaikh F; Woo KM; Zhang Z; Foster A; Rosenzweig KE; Gewanter R; Huang J; Rimner A
Clin Lung Cancer; 2016 May; 17(3):177-183.e2. PubMed ID: 26602271
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiation therapy versus sublobar resection for stage I NSCLC.
Ackerson BG; Tong BC; Hong JC; Gu L; Chino J; Trotter JW; D'Amico TA; Torok JA; Lafata K; Chang C; Kelsey CR
Lung Cancer; 2018 Nov; 125():185-191. PubMed ID: 30429018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
